FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Search Results

Paclitaxel Injection (protein-bound particles)
Status: Currently in Shortage
»Date first posted: 10/05/2021
»Therapeutic Categories: Oncology

Bristol Myers Squibb Co. (Revised 01/07/2022)

Company Contact Information:

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
Abraxane® 100 mg, single dose vial (NDC 68817-134-50) Temporarily on allocation through beginning of March 2022. Manufacturing delay

BMS Product Supply Information


Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English